European Journal of Clinical Pharmacology

, Volume 39, Supplement 1, pp S29–S33 | Cite as

Age-related antihypertensive and haemodynamic effects of verapamil SR: Clinical results and effects on atrial natriuretic peptide

  • R. Antonicelli
  • P. F. Tomassini
  • P. Galletti
  • C. Gambini
  • M. Marini
  • L. Amadio
  • E. Paciaroni
Poster Presentation


The antihypertensive effect of the calcium-antagonist verapamil was investigated in two groups of patients, adult hypertensives (AH, < 65 years of age) and elderly hypertensives (EH, > 65 years of age), who were treated with 240 mg p.o. sustained-release (SR) verapamil for 4 months. Arterial blood pressure was significantly reduced in both groups: the responders’ rate was 65% in the AH group and 82% in the EG group. The heart rate was slightly but not significantly reduced. An improvement in cardiac haemodynamics was observed [cardiac index (CI), from 3.00± 0.51 to 3.25 ± 0.83 ml min−1 m−2 in AH and from 2.35 ± 1.08 to 3.04 ± 0.86 ml min−1 m−2 in EG]. We also evaluated the plasma concentrations of atrial natriuretic peptide (ANP) before and after treatment; ANP levels increased significantly only in the EH group. No serious side effects occurred. In conclusion, verapamil SR provided effective and well-tolerated anti-hypertensive treatment in both adult and elderly patients.

Key words

hypertension verapamil haemodynamics atrial natriuretic peptide elderly clinical trial 


  1. 1.
    Zachariah PK, Sheps SG, Schirger A (1986) Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension. Am J Cardiol 57: 74D-79DPubMedCrossRefGoogle Scholar
  2. 2.
    Reinfrank J, Eckardt A, Hahn KJ (1987) Long term multicenter study of verapamil SR 240 mg in hypertension. In: Fleckenstein A, Laragh JH (eds) Hypertension — the next decade: verapamil in focus. Churchull-Livingstone, Edinburgh London, pp 307–313Google Scholar
  3. 3.
    Abernethy DR, Schwartz JB, Todd EL, Lichi R, Snow E (1986) Verpamil pharmacodynamics and disposition in young and elderly hypertensive patients. Ann Intern Med 105: 329–332PubMedGoogle Scholar
  4. 4.
    Buhler FR, Hulthen UL, Kiowsky W, Bolli P (1987) Greater antihypertensive efficacy of the calcium channel inhibitor verapamil in older and low renin patients. Clin Sci 439–442Google Scholar
  5. 5.
    Cox PJ, O’Boyle CA, Mee F, Kelly J, Atkins N, Coakley D, O’Brein ET, O’Malley K (1988) The antihypertensive efficacy of verapamil in evaluation by ambulatory blood pressure measurement. J Hum Hpyertens 2: 41–47Google Scholar
  6. 6.
    Richards AM, Tonolo G, Leckie BJ, Robertson IS (1987) Radio-immunoassay for plasma alpha human atrial natriuretic peptide: a comparison of direct and pre-extracted methods. J Hypertens 5: 227–236PubMedCrossRefGoogle Scholar
  7. 7.
    Kirk RE (1968) Experimental design: procedures for the behavioural sciences. Brooks/Cole, Belmont, CaliforniaGoogle Scholar
  8. 8.
    SPSS Inc. (1986) SPSS-x user’s guide. McGraw-Hill, New YorkGoogle Scholar
  9. 9.
    Lennart Hulthen U, Bolli P, Amann FW, Kiowski W, Buhler FR (1982) Verapamil-induced vasodilatation is enhanced in essential hypertension. J Cardiovasc Pharmacol 4: S313-S318CrossRefGoogle Scholar
  10. 10.
    Schmieder RE, Messerli FN, Garavaglia GE, Nunez BD (1987) Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 75: 1030–1036PubMedGoogle Scholar
  11. 11.
    Lang RE, Tholken HG, Anten D, Luit FC, Unger TH (1985) Atrial natriuretic factor: a circulating hormone stimulated by volume loading. Nature 314: 264–266PubMedCrossRefGoogle Scholar
  12. 12.
    Ledsome JR, Wilson N, Couneya CA, Rankin AJ (1985) Release of atrial natriuretic peptide by atrial distension. Can J Physiol Pharmacol 63: 739–742PubMedGoogle Scholar
  13. 13.
    Agnoletti G, Rodela A, Ferrari R, Harrys P (1987) Release of atrial natriuretic peptide-like immunoreactive material during stretching of the rat atrium in vitro. J Mol Cell Cardiol 19: 217–220PubMedCrossRefGoogle Scholar
  14. 14.
    Burnett JC, Kao PC, Hu D, Heser DW, Reeder GS (1986) Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231: 1145–1147PubMedCrossRefGoogle Scholar
  15. 15.
    Nakaoka H, Imataka K, Amano M, Fujii J, Yamaji T (1985) Plasma levels of atrial natriuretic factor in patients with congestive heart failure. N Engl J Med 313: 892–893PubMedCrossRefGoogle Scholar
  16. 16.
    Rascher W, Tulassay T, Lang RE (1985) Atrial natriuretic peptide in plasma of volume overloaded children with chronic renal failure. Lancet I: 303–305CrossRefGoogle Scholar
  17. 17.
    Yamaji T, Ishibashi M, Nakaoka H, Amano M, Fujii J (1985) Possible role for atrial natriuretic peptide in polyuria associated with paroxysmal atrial arrhythmias. Lancet I: 1211CrossRefGoogle Scholar
  18. 18.
    Schiaffrin EI, Gutkowska J, Kuchel O, Cantin M, Genest J (1985) Plasma concentration of atrial natriuretic factor in patients with paroxysmal atrial tachycardia. N Engl J Med 312: 1196–1197CrossRefGoogle Scholar
  19. 19.
    Saccomanno G, Antonicelli R, Campanari G, Paciaroni E (1989) Effects of mode and rate of pacing on atrial natriuretic peptide release in patients with permanent pacemakers. Curr Ther Res 46(4): 762–767Google Scholar
  20. 20.
    Sagnella GA, Markandu ND, Shore AC, MacGregor GA (1986) Raised circulating levels of atrial natriuretic peptides in essential hypertension. Lancet I: 179–181CrossRefGoogle Scholar
  21. 21.
    Kohono M, Yasunai K, Matsuura T, Takeda T (1987) Circulating atrial natriuretic polypeptide in essential hypertension. Am Heart J 113: 1160–1163CrossRefGoogle Scholar
  22. 22.
    Larochelle P, Cusson J, Gutkowska EL, Schiffrin P, Genest J, Cantin M (1987) Plasma atrial natriuretic factor concentrations in essential and renovascular hypertension. Br Med J 249: 1249–1252CrossRefGoogle Scholar
  23. 23.
    Nilsson P, Schersten B, Melander A, Lindholm L, Horn R, Hesch RD (1988) Atrial natriuretic peptide and blood pressure in a geographically defined population. Lancet II: 883–886Google Scholar
  24. 24.
    Sugawara A, Nakao K, Sakamoto M (1985) Plasma concentration of atrial natriuretic polypeptide in essential hypertension. Lancet II: 1426–1427CrossRefGoogle Scholar
  25. 25.
    Antonicelli R, Melappioni M, Campanari G, Foschi F, Paciaroni E (1989) Evaluation of plasmatic ANP levels in subjects affected by essential arterial hypertension and in a group of patients undergoing dialysis. Int J Cardiol 25 [Suppl 1]: 21–29Google Scholar
  26. 26.
    Knorr M, Locher R, Strimpel M, Edmonds D, Vetter W (1986) Effects of ANP on angiotensin II-induced increase of cytosolic free calcium in cultured smooth muscle cells. J Hypertens 4 [Suppl 2]: S67-S69Google Scholar
  27. 27.
    Winquist RJ (1985) The relaxant effects of ANF on vascular smooth muscle. Life Sci 37: 1081–1087PubMedCrossRefGoogle Scholar
  28. 28.
    Van Bortel LMAB, Schiffers PMH, Boehm ROB, Mooy JMV, Rahn KH (1989) The influence of a chronic treatment with verapamil on plasma human ANP levels in young and elderly hypertensive patients (abstract). Proceedings of the 4th European Meeting on Hypertension, Milan, June 18–21Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • R. Antonicelli
    • 1
  • P. F. Tomassini
    • 1
  • P. Galletti
    • 3
  • C. Gambini
    • 1
  • M. Marini
    • 1
  • L. Amadio
    • 2
  • E. Paciaroni
    • 1
  1. 1.Hypertension Center, AnconaI. N. R. C. A. (Italian National Research Centre on Aging)AnconaItaly
  2. 2.Center of Demography and StatisticsI. N. R. C. A. (Italian National Research Centre on Aging)AnconaItaly
  3. 3.Medical DepartmentKnoll FarmaceuticiMilanItaly

Personalised recommendations